These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 35800178)
21. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival? Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470 [TBL] [Abstract][Full Text] [Related]
22. Diagnostic Performance of Modified Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Patients Without Risk Factors for Hepatocellular Carcinoma: Comparison With World Federation for Ultrasound in Medicine and Biology Guideline. Zhang Y; Li Q; Li L; Hong Y; Qiang B; Yu Y; Guo R; Deng H; Han X; Zou X; Guo Z; Zhou J Ultrasound Med Biol; 2024 Feb; 50(2):243-250. PubMed ID: 37985306 [TBL] [Abstract][Full Text] [Related]
23. Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features. Jiang H; Song B; Qin Y; Chen J; Xiao D; Ha HI; Liu X; Oloruntoba-Sanders O; Erkanli A; Muir AJ; Bashir MR Eur Radiol; 2021 Jun; 31(6):3638-3648. PubMed ID: 33245494 [TBL] [Abstract][Full Text] [Related]
24. Performance of current versus modified CEUS LI-RADS in the diagnosis of non-hepatocellular carcinoma malignancies. Wen R; Huang F; Lin P; Gao R; Pang J; Wu Y; Yin H; Tang Z; Ma Z; He Y; Yang H Abdom Radiol (NY); 2023 Dec; 48(12):3688-3695. PubMed ID: 37726380 [TBL] [Abstract][Full Text] [Related]
25. Diagnostic performance of intravascular perfusion based contrast-enhanced ultrasound LI-RADS in the evaluation of hepatocellular carcinoma. Zuo D; Yang K; Wu S Clin Hemorheol Microcirc; 2021; 78(4):429-437. PubMed ID: 33867358 [TBL] [Abstract][Full Text] [Related]
26. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma. Li S; Zhou L; Chen R; Chen Y; Niu Z; Qian L; Fang Y; Xu L; Xu H; Zhang L Clin Radiol; 2021 Feb; 76(2):161.e1-161.e10. PubMed ID: 33198943 [TBL] [Abstract][Full Text] [Related]
27. LR-M Observations on Contrast-Enhanced Ultrasound: Detection of Hepatocellular Carcinoma Using Additional Features in Comparison With Current LI-RADS Criteria. Xian MF; Huang Y; Xie WX; Pan KM; Zeng D; Huang H; Li MD; Xie XY; Kuang M; Lu MD; Chen LD; Wang W AJR Am J Roentgenol; 2022 Jul; 219(1):76-85. PubMed ID: 34910538 [No Abstract] [Full Text] [Related]
28. Diagnosis of Non-Hepatocellular Carcinoma Malignancies in Patients With Risks for Hepatocellular Carcinoma: CEUS LI-RADS Versus CT/MRI LI-RADS. Hu YX; Shen JX; Han J; Mao SY; Mao RS; Li Q; Li F; Guo ZX; Zhou JH Front Oncol; 2021; 11():641195. PubMed ID: 33912456 [TBL] [Abstract][Full Text] [Related]
29. Analysis of comparative performance of CEUS and CECT/MR LI-RADS classification: Can CEUS dichotomize LI-RADS indeterminate lesions on CT or MRI? Tan Z; Teoh WC; Wong KM; Wansaicheong GK; Sandrasegaran K Clin Imaging; 2020 Jun; 62():63-68. PubMed ID: 32070868 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of the Time Difference Method in Identifying Hepatocellular Carcinoma in Current CEUS LR-M Category Nodules. Shao LJ; Wang YJ; Yin SS; Jiang BB; Liu YH; Wang JC; Yang W; Wu W; Yan K Ultrasound Med Biol; 2024 Apr; 50(4):502-508. PubMed ID: 38246805 [TBL] [Abstract][Full Text] [Related]
31. Impact of Revision of the LR-M Criteria on the Diagnostic Performance of Contrast-Enhanced Ultrasound LI-RADS. Ding J; Qin Z; Zhou Y; Zhou H; Zhang Q; Wang Y; Jing X; Wang F Ultrasound Med Biol; 2021 Dec; 47(12):3403-3410. PubMed ID: 34598799 [TBL] [Abstract][Full Text] [Related]
32. Comparison between M-score and LR-M in the reporting system of contrast-enhanced ultrasound LI-RADS. Chen LD; Ruan SM; Lin Y; Liang JY; Shen SL; Hu HT; Huang Y; Li W; Wang Z; Xie XY; Lu MD; Kuang M; Wang W Eur Radiol; 2019 Aug; 29(8):4249-4257. PubMed ID: 30569182 [TBL] [Abstract][Full Text] [Related]
33. Diagnostic Accuracy of Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for Differentiating Between Hepatocellular Carcinoma and Other Hepatic Malignancies in High-Risk Patients: A Meta-Analysis. Li J; Yang L; Ma L; Lu Q; Luo Y Ultraschall Med; 2021 Apr; 42(2):187-193. PubMed ID: 33307595 [TBL] [Abstract][Full Text] [Related]
34. Focal liver lesions in cirrhosis: value of contrast-enhanced ultrasonography compared with Doppler ultrasound and alpha-fetoprotein levels. D'Onofrio M; Faccioli N; Zamboni G; Malagò R; Caffarri S; Fattovich G; Mucelli RP Radiol Med; 2008 Oct; 113(7):978-91. PubMed ID: 18779929 [TBL] [Abstract][Full Text] [Related]
35. Tumor size-based validation of contrast-enhanced ultrasound liver imaging reporting and data system (CEUS LI-RADS) 2017 for hepatocellular carcinoma characterizing. Pan JM; Chen W; Zheng YL; Cheng MQ; Zeng D; Huang H; Huang Y; Xie XY; Lu MD; Kuang M; Hu HT; Chen LD; Wang W Br J Radiol; 2021 Oct; 94(1126):20201359. PubMed ID: 34545763 [TBL] [Abstract][Full Text] [Related]
36. Contrast-enhanced ultrasound LI-RADS 2017: comparison with CT/MRI LI-RADS. Ding J; Long L; Zhang X; Chen C; Zhou H; Zhou Y; Wang Y; Jing X; Ye Z; Wang F Eur Radiol; 2021 Feb; 31(2):847-854. PubMed ID: 32803416 [TBL] [Abstract][Full Text] [Related]
37. Can Modifications of LR-M Criteria Improve the Diagnostic Performance of Contrast-Enhanced Ultrasound LI-RADS for Small Hepatic Lesions up to 3 cm? Huang W; Wen R; Wu Y; Lin P; Guo D; Peng Y; Liu D; Mou M; Chen F; Huang F; Yang H; He Y J Ultrasound Med; 2023 Oct; 42(10):2403-2413. PubMed ID: 37269201 [TBL] [Abstract][Full Text] [Related]
38. Contrast-enhanced US diagnostic algorithm of hepatocellular carcinoma in patients with occult hepatitis B. Huang Y; Li W; Hu HT; Ruan SM; Xian MF; Xie XY; Lu MD; Kuang M; Chen LD; Wang W Abdom Radiol (NY); 2022 Feb; 47(2):608-617. PubMed ID: 34800160 [TBL] [Abstract][Full Text] [Related]
39. Identification of the origin of tumor in vein: comparison between CEUS LI-RADS v2017 and v2016 for patients at high risk. Tong WJ; Cheng MQ; Lin MX; Hu HT; Pan JM; Huang H; Wang Y; Xie XY; Lu MD; Kuang M; Huang Y; Wang W BMC Med Imaging; 2022 Oct; 22(1):186. PubMed ID: 36309665 [TBL] [Abstract][Full Text] [Related]
40. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions. Min JH; Kim JM; Kim YK; Kim H; Choi GS; Kang TW; Cha D; Hwang JA; Ko SE; Ahn S Eur Radiol; 2022 Feb; 32(2):912-922. PubMed ID: 34345947 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]